Singapore, June 7 -- Many drugs fail in clinical trials due to discrepancies between pre-clinical and clinical outcome, often stemming from the inability of animal models to replicate human biological responses accurately. Instead, to overcome this challenge, EHTs derived from human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) have been increasingly utilised to model cardiac diseases and test candidate drugs.

However, while polydimethylsiloxane (PDMS) is favoured for its flexibility and biocompatibility, its high absorptive property significantly distorts pharmacodynamic assessments. To address this, the researchers developed a PS-based EHT device with dramatically lower compound absorption. Although PS is inherently stiffer ...